Q-omics provides the consensus-scored PIK3R6 profile across patient tissues and cancer cell-line models. PIK3R6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PIK3R6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PIK3R6 protein abundance shows 20,224 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where PIK3R6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3R6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3R6 survival associations across molecular data types. PIK3R6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3R6 RNA expression–survival associations across cancer types. High PIK3R6 expression shows unfavorable associations in LGG, KIRC and KIRP, but favorable associations in HNSC, SKCM and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PIK3R6 RNA expression.
This table summarizes PIK3R6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PIK3R6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3R6 shows higher tumor expression in KIRC, THCA, KIRP, LIHC, HNSC and STAD. The KIRC box plot shows higher PIK3R6 RNA expression in tumor versus normal tissue (log2 FC = +2.079, t-test p < 0.001).
This table shows molecular features associated with PIK3R6 in patient tissues and cancer cell lines. In patient samples, PIK3R6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3R6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
